后程加速超分割放疗联合复方氟尿嘧啶多相脂质体治疗食管癌

Late accelerated hyperfractionated radiotherapy combined with compound polyphase liposome of 5-fluorouracil for esophageal carcinoma

目的观察后程加速超分割放疗(LCAF)联合口服复方氟尿嘧啶多相脂质体(FPLC)治疗食管癌的近期疗效。方法将110例食管鳞癌患者随机分为三组,A组予LCAF联合口服FPLC治疗,B组仅予LCAF,C组予常规分割放疗(CF)。结果三组近期疗效(CR+PR)、局部控制率、3a生存率有显著性差异,A组优于B组,B组优于C组;急性毒副反应A、B组高于C组,但A、B组间无显著差异;三组的晚期放疗反应和并发症的发生率无明显差异;A、B组死于肿瘤未控或复发的比率明显低于C组,三组死于远处转移者无明显差异。结论LCAF联合FPLC可提高食管癌的局部控制率和生存率,虽毒性增加但不影响治疗过程,远期疗效仍需进一步观察。

[Objective] To evaluate the effect of late course acceletated hyperfractionated radiotherapy（LACF） combined with compound polyphase liposome of 5-fluorouracil（FPLC） on esophageal carcinoma.[Methods]One hundred and ten cases of esophageal cancer patients were randomly divided into three groups.Group A was treated with LACF combined with FPLC;group B with LACF alone,and group C with conventional radiotherapy（CF） alone.[Results]The short-term results（complete response and partial response）,tumor local control rate and 3-year survival rate of three groups were significantly different,group A was superior to group B,and group B was superior to group C.The accident of acute adverse effects in group A and group B were higher than those in group C,but there was no statistically significant difference between the group A and B.There was no statistically significant difference in late side effect among the three groups.Less patients died of cancer recurrence and progression in group A and B than in group C.There was no statistically difference in distant metastasis among three groups.[Conclusion] The combination treatment of FPLC and LACF can improve the local control of tumor growth and the survival rate in esophageal cancer patients.Though the acute reaction in combined treatment is more than conventional irradiation,it does not affect the treatment.The value of combined treatment in long-term results needs further study in clinic.